Gemcitabine continuation maintenance or erlotinib switch maintenance significantly reduces disease progression in patients with advanced NSCLC treated with cisplatin-gemcitabine as first-line chemotherapy. Response to induction chemotherapy may affect OS only for continuation maintenance.
M Mi ig gr ra at to or ry y b br ro on nc ch hi io ol li it ti is s o ob bl li it te er ra an ns s o or rg ga an ni iz zi in ng g p pn ne eu um mo on ni ia a a af ft te er r u un ni il la at te er ra al l r ra ad di ia at ti io on n t th he er ra ap py y f fo or r b br re ea as st t c ca ar rc ci in no om ma a
Second-line treatment for NSCLC is more cost-effective with docetaxel than with pemetrexed. Both strategies have acceptable cost-effectiveness ratios compared with commonly used and reimbursed regimens for advanced NSCLC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.